Published in Transplantation on February 15, 2013
Plasma cell neoplasms in US solid organ transplant recipients. Am J Transplant (2013) 0.92
Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology. BMC Cancer (2014) 0.87
Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol (2013) 0.83
Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2014) 0.75
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem (2001) 3.94
Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood (2001) 2.93
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
How I treat EBV lymphoproliferation. Blood (2009) 2.18
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Monoclonal and oligoclonal gammopathies in heart-transplant recipients. Clin Chem (1991) 1.54
Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival. Bone Marrow Transplant (2007) 1.53
Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol (2008) 1.52
Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol (2006) 1.40
Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol (2000) 1.36
Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol (2010) 1.36
High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS (1994) 1.29
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood (2009) 1.20
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant (2005) 1.13
Posttransplantation lymphoproliferative disorders. Arch Intern Med (2003) 1.09
Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation (2001) 1.08
Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. J Proteome Res (2010) 1.07
Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood (1989) 1.03
Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood (2011) 1.02
Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant (2008) 1.00
Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant (2009) 0.98
Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods (2002) 0.97
Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplant Proc (2004) 0.93
Paraproteinemia after hematopoietic stem cell transplantation. Leuk Lymphoma (2004) 0.89
Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol (2011) 0.88
High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation. Transplantation (1988) 0.87
Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder. Am J Transplant (2012) 0.87
Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg (1996) 0.87
Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease. Clin Transplant (2009) 0.86
Clinical relevance of circulating donor-specific HLA antibodies. Curr Opin Organ Transplant (2010) 0.86
Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant (2006) 0.86
Frequent occurrence of monoclonal gammopathies with an imbalanced light-chain ratio following bone marrow transplantation. Transplantation (1987) 0.85
Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder. Clin Transplant (2005) 0.84
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Prediction error estimation: a comparison of resampling methods. Bioinformatics (2005) 6.41
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
On criteria for evaluating models of absolute risk. Biostatistics (2005) 5.71
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med (2010) 4.30
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer (2003) 4.02
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res (2005) 3.33
Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol (2007) 3.32
The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 3.29
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
CARs on track in the clinic. Mol Ther (2011) 2.86
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Post-transplant lymphoproliferative disorders. Annu Rev Med (2005) 2.82
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst (2008) 2.64
MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst (2005) 2.57
Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol (2008) 2.56
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA (2007) 2.51
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis (2003) 2.42
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol (2011) 2.34
Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med (2010) 2.33
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2007) 2.33
Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA (2011) 2.31
Elevated risk of lung cancer among people with AIDS. AIDS (2007) 2.20
Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer (2007) 2.16
Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med (2011) 2.16
Adoptive T cell therapy of cancer. Curr Opin Immunol (2010) 2.13
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol (2011) 2.11
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood (2007) 2.11
Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood (2010) 2.06
Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol (2006) 2.05
Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood (2004) 2.05
Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol (2007) 2.02
Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. Clin Infect Dis (2012) 2.01
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood (2010) 1.98
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 1.98
Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant (2009) 1.97
Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J Natl Cancer Inst (2013) 1.96
Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev (2008) 1.96
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood (2010) 1.96
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (2013) 1.95
Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst (2011) 1.94
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 1.93
Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst (2006) 1.90
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood (2002) 1.89
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS (2014) 1.86
Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. Exp Hematol (2012) 1.85
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother (2010) 1.81
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology (2009) 1.80
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood (2008) 1.78